Safety and PK/PD of TG-0054 in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients
A phase II study to evaluate the safety, pharmacokinetics, and hematopoietic stem cell mobilization of TG-0054 in patients with multiple myeloma, non-Hodgkin lymphoma or Hodgkin disease.
Multiple Myeloma|Non-Hodgkin Lymphoma|Hodgkin Disease
DRUG: TG-0054 (2.24 mg/kg)|DRUG: TG-0054 (3.14 mg/kg)
Number of Patients Who Achieved Mobilization Success of Hematopoietic Stem Cells in Patients With Multiple Myeloma (MM), Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD)., Patients who met the target CD34+ cell collection of ≧2 x 106 cells/kg after two apheresis sessions were classified as achieving mobilization success., 1 week
Maximum Plasma Concentration (Cmax) of TG-0054 in 12 Consented Patients With MM, NHL or HD., Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method., 36 hrs after infusion|Fold Increase of Circulating CD34+ Cell Counts in Peripheral Blood., Baseline, 3 hours and 6 hours after infusion|Time at Which Maximum Plasma Concentration is Observed (Tmax) of TG-0054 in 12 Consented Patients With MM, NHL or HD., Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method., 36 hrs after infusion|Terminal Elimination Half-life (t1/2) of TG-0054 in 12 Consented Patients With MM, NHL or HD., Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method., 36 hrs after infusion|Terminal Elimination Rate Constant (λz) of TG-0054 in 12 Consented Patients With MM, NHL or HD., Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method., 36 hrs after infusion|The Area Under the Plasma Concentration Time Curve (AUC) From 0 Hours to Time t of TG-0054 in 12 Consented Patients With MM, NHL or HD., Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method., 36 hrs after infusion|The Area Under the Plasma Concentration Time Curve (AUC) From 0 Hours to Infinity of TG-0054 in 12 Consented Patients With MM, NHL or HD., Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method., 36 hrs after infusion|Clearance (CL) of TG-0054 in 12 Consented Patients With MM, NHL or HD., Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method., 36 hrs after infusion|Volume of Distribution at the Terminal State (Vz) of TG-0054 in 12 Consented Patients With MM, NHL or HD., Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method., 36 hrs after infusion|Volume of Distribution at Steady State (Vss) of TG-0054 in 12 Consented Patients With MM, NHL or HD., Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method., 36 hrs after infusion|Circulating CD34+ Cell Counts in Peripheral Blood., Baseline, 3 hours and 6 hours after infusion
A phase II study to evaluate the safety, pharmacokinetics, and hematopoietic stem cell mobilization of TG-0054 in patients with multiple myeloma, non-Hodgkin lymphoma or Hodgkin disease.